阿朱巴:主监管机构在结肠直肠癌中弥合了EMT和免疫逃避
Wenhui Shen1, Minghui Cui2, Xiaoqian Liao3
1Department of Head Neck and Thyroid, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, 450008, China, zzu.edu.cn.
AJUBA通过促进M2巨细胞透,将结直肠癌的EMT与免疫逃避联系起来. 这种蛋白质是一种预后生物标志物和转移性CRC的潜在治疗点.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
背景情况:
- 表皮-介质细胞过渡 (EMT) 驱动着结直肠癌 (CRC) 转移和免疫逃避.
- 在EMT和CRC免疫微环境之间存在的分子联系尚未得到充分理解.
研究的目的:
- 在CRC中确定连接EMT和免疫调节的关键调节器.
- 调查AJUBA在CRC进展和免疫逃避中的作用.
主要方法:
- 集成的多队列转录和单细胞RNA-seq数据使用机器学习.
- 通过qPCR,西部涂抹,IHC和体内异种移植模型验证了AJUBA的表达和功能.
- 使用ssGSEA和CIBERSORT评估免疫透,以及空间转录学.
主要成果:
- AJUBA在EMT激活的CRC细胞中升级调节,并在免疫排除的中与癌症相关的纤维细胞结合.
- AJUBA表达与M2巨细胞透和VEGF/NOTCH信号传递相关.
- 低AJUBA抑制瘤生长和M2巨细胞的丰富性;高AJUBA预测整体存活率较低.
结论:
- AJUBA 是一个关键的调节器,将EMT与CRC中的免疫调节和巨细胞极化联系起来.
- AJUBA通过将EMT与益血管性信号相结合来促进免疫逃避.
- AJUBA作为预后生物标志物和转移性CRC的潜在治疗点.
更多相关视频
11:02Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
09:29Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
相关概念视频
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Adaptive Mechanisms in Cancer Cells
Tumor Immunotherapy
The Tumor Microenvironment
The Tumor Microenvironment
Cancer Stem Cells and Tumor Maintenance
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
